| Literature DB >> 30618415 |
Kadiliya Jueraitetibaike1, Zheng Ding2, Dan-Dan Wang1, Long-Ping Peng3, Jun Jing1, Li Chen1, Xie Ge1, Xu-Hua Qiu1, Bing Yao1.
Abstract
Vitamin D deficiency is a common health issue around the world. We therefore evaluated the associations of semen quality with both serum and seminal plasma vitamin D levels and studied the mechanisms underlying these by incubating spermatozoa with 1,25(OH)2D In vitro. Two hundred and twenty-two men were included in our study. Vitamin D was detected using an electrochemiluminescence method. Spermatozoa used for In vitro experiments were isolated by density gradient centrifugation. Positive relationships of serum 25(OH)D with semen volume and seminal plasma fructose were identified. Seminal plasma 25(OH)D level showed no relationship with serum 25(OH)D level, while it was inversely associated with sperm concentration and positively correlated with semen volume and sperm kinetic values. In vitro, sperm kinetic parameters increased after incubation with 1,25(OH)2D, especially upon incubation for 30 min with it at a concentration of 0.1 nmol l-1. Under these incubation conditions, the upward migration of spermatozoa increased remarkably with increasing adenosine triphosphate (ATP) concentration. The concentration of cyclic adenosine monophosphate (cAMP) and the activity of protein kinase A (PKA) were both elevated, and the PKA inhibitor, N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (H89) reversed the increase of ATP production. The concentrations of cytoplasmic calcium ions and nicotinamide adenine dinucleotide (NADH) were both enhanced, while mitochondrial calcium uniporter (MCU) inhibitor, Ruthenium 360 (Ru360) did not reverse the increase of ATP production. Therefore, seminal plasma vitamin D may be involved in regulating sperm motility, and 1,25(OH)2D may enhance sperm motility by promoting the synthesis of ATP both through the cAMP/PKA pathway and the increase in intracellular calcium ions.Entities:
Keywords: adenosine triphosphate; seminal plasma; sperm motility; vitamin D
Mesh:
Substances:
Year: 2019 PMID: 30618415 PMCID: PMC6628736 DOI: 10.4103/aja.aja_105_18
Source DB: PubMed Journal: Asian J Androl ISSN: 1008-682X Impact factor: 3.285
Characteristics of the men included (n=222)
| Semen volume (ml)# | 222 | 3.80 (3.10–4.80) |
| Sperm concentration (106 ml−1)# | 222 | 42.85 (21.75–62.23) |
| Sperm motility (%) | 222 | 35.27±13.60 |
| Progressive motile spermatozoa (%) | 222 | 29.97±11.31 |
| VSL (µm s−1) | 222 | 23.71±3.66 |
| VCL (µm s−1) | 222 | 31.83±4.54 |
| VAP (µm s−1) | 222 | 25.61±3.69 |
| Duration of abstinence (day)# | 222 | 4 (3–5) |
| Morphologically normal (%)# | 185 | 5.61 (4.69–6.16) |
| Intact acrosome rate (%)# | 186 | 59.82 (57.33–62.74) |
| Serum 25(OH) D (ng ml−1)# | 160 | 26.17 (19.61–31.99) |
| Seminal plasma 25(OH) D (ng ml−1)# | 192 | 6.55 (4.30–9.62) |
| Serum AMH (ng ml−1)# | 157 | 8.94 (6–14.4) |
| Seminal plasma AMH (ng ml−1)# | 92 | 0.35 (0.15–1.04) |
| Serum INHB (pg ml−1)# | 96 | 94.80 (73.50–122.50) |
| Seminal plasma INHB (pg ml−1)# | 94 | 97.45 (55.58–177.50) |
| Seminal plasma fructose (mmol l−1) | 166 | 18.39±7.70 |
| Seminal plasma α-glucosidase (U l−1) | 167 | 347.45±151.98 |
All the men lacked serious comorbidities. Data are reported as mean and s.d. for variables normally distributed or as median and interquartile range for variables not normally distributed. #Indicates that the normality test revealed a lack of conformity to a normal distribution. VSL: straight-line velocity; VCL: curvilinear velocity; VAP: average path velocity; AMH: anti-Müllerian hormone; INHB: inhibin B; s.d.: standard deviation
The correlations between the level of serum or seminal plasma 25-hydroxyvitamin D and sperm parameter values (n=222)
| Age (year)a | −0.034 | 0.688 | −0.037 | 0.640 |
| BMI (kg m−2) | 0.134 | 0.092 | 0.101 | 0.163 |
| Duration of abstinence (day)a | 0.066 | 0.407 | −0.028 | 0.699 |
| Semen volume (ml)a | 0.229 | 0.004** | 0.271 | 0** |
| Sperm concentration (×106 ml−1)a | −0.020 | 0.806 | −0.174 | 0.016* |
| Sperm motility (%) | −0.015 | 0.853 | 0.124 | 0.087 |
| Progressive motile spermatozoa (%) | −0.025 | 0.757 | 0.104 | 0.150 |
| VSL (µm s−1) | −0.039 | 0.624 | 0.218 | 0.002** |
| VCL (µm s−1) | −0.059 | 0.457 | 0.208 | 0.004** |
| VAP (µm s−1) | −0.060 | 0.454 | 0.222 | 0.002** |
| Morphologically normal (%)a | 0.039 | 0.633 | 0.020 | 0.799 |
| Intact acrosomes (%)a | 0.001 | 0.992 | −0.010 | 0.896 |
| Serum AMH (ng ml−1)a | 0.102 | 0.204 | 0.045 | 0.617 |
| Seminal plasma AMH (ng ml−1)a | 0.146 | 0.169 | −0.088 | 0.429 |
| Serum INHB (pg ml−1)a | 0.171 | 0.099 | 0.073 | 0.500 |
| Seminal plasma INHB (pg ml−1)a | 0.081 | 0.443 | 0.171 | 0.116 |
| Seminal plasma fructose (mmol l−1) | 0.257 | 0.002** | −0.004 | 0.963 |
| Seminal plasma a-glucosidase (U l−1) | −0.132 | 0.116 | −0.108 | 0.193 |
| Seminal plasma 25(OH)D (ng ml-1)a | 0.079 | 0.372 | - | - |
aIndicates that the normality test revealed a lack of conformity to a normal distribution. *P<0.05 and **P<0.01 for bilateral test. VSL: straight-line velocity; VCL: curvilinear velocity; VAP: average path velocity; AMH: anti-Müllerian hormone; INHB: inhibin B; 25(OH)D: 25-hydroxyvitamin D; BMI: body mass index